WHWK

Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.

Wall Street analysts forecast WHWK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for WHWK is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Whitehawk Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Whitehawk Therapeutics Inc. EPS for the last quarter amounts to -0.26 USD, decreased -43.48 % YoY.

Whitehawk Therapeutics Inc (WHWK) has 40 emplpoyees as of December 15 2025.

Today WHWK has the market capitalization of 109.34M USD.